Trastuzumab Biosimilar Market Analysis

The trastuzumab biosimilar market is segmented based on application type into breast cancer, colorectal cancer, leukemia, and others, out of which, the breast cancer segment is anticipated to grab the largest share by the end of 2021 on account of increasing incidence and increasing prevalence of breast cancer globally. Moreover, colorectal cancer segment is also projected to contribute to the growth of the segment during the forecast period due to the rising incidence in colon and rectal cancer worldwide. According to World Health Organization, the most common in 2020 (in terms of new cases of cancer) were breast cancer (2.26 million cases), followed by colon and rectum cancer (1.93 million cases) on the third number.

On the basis of distribution channel, the offline segment in the global trastumuzab biosimilar market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the presence of retail and hospital pharmacies and an expanded customer base. Although, online segment is also expected to contribute to the market due to increasing dependence on e-commerce platforms and rising internet penetration.

Our in-depth analysis of the global market includes the following segments: